Condition: Proliferative Glomerulonephritis With Monoclonal IgG Deposits · Sponsor: Mayo Clinic
The purpose of this research is to study the safety and efficacy of daratumumab in inducing complete or partial remission in people with proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID).
This description comes directly from the study's public registry record.
Corbyn Bendtsen · 507-284-0366 · bendtsen.corbyn@mayo.edu
Nicholas Geroux · 507-266-0956 · geroux.nicholas@mayo.edu
Always discuss trial participation with your own doctor first.
| Mayo Clinic | Jacksonville, Florida, United States | Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
| University North Carolina at Chapel Hill | Chapel Hill, North Carolina, United States | Recruiting |
| Oregon Health and Science University | Portland, Oregon, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05654506